Results 111 to 120 of about 2,524 (195)

Clinical and Economic Impact of Nirsevimab and Bivalent Maternal Vaccine Against RSV Infections in Infants in Italy. [PDF]

Clinicoecon Outcomes Res
Bini C, Marcellusi A, Muzii B, Soudani S, Trotta S, Parisi S, Bozzola E, Bonanni P, Boccalini S.   +8 more
europepmc   +1 more source

Correction: Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial Virus. [PDF]

Infect Dis Ther
Alharbi AS, Abu-Shraie N, Al Abdulkarim H, Alharbi IH, Averin A, Law AW, Mendes D, Quinn E, Zayed M, Behiry A, Haridy H, Mousa M.   +11 more
europepmc   +1 more source

Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy

Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to ...
Marcellusi, A, Bozzola, E, Boccalini, S, Baraldi, E, Kieffer, A, Muzii, B, Soudani, S, Orfeo, L, Beuvelet, M, Bini, C, Midulla, F, Bonanni, P, Bozzola E, Boccalini S, Bonanni P, Orfeo L., Marcellusi A, Baraldi E, Kieffer A, Midulla F, Beuvelet M, Muzii B, Bini C, Soudani S   +23 more
core   +1 more source

The Effectiveness of Nirsevimab on Antibiotic Use in Children Using Target Trial Emulation. [PDF]

Clin Infect Dis
Ahmed MM, Joerger T, Wang Z, Li Y, Gerber JS.   +4 more
europepmc   +1 more source

Nirsevimab in the New Era of RSV Prevention: Current Evidence, Emerging Challenges, and Future Perspectives. [PDF]

Medicina (Kaunas)
Vasou M, Sokou R, Kafalidis G, Tsantes AG, Moutsopoulou RA, Grigoropoulos F, Katsianou E, Xixi NA, Magklara EP, Leontari K, Iliodromiti Z, Boutsikou T, Iacovidou N.   +12 more
europepmc   +1 more source

Clinical Profile of RSV Breakthrough Infections After Nirsevimab Introduction. [PDF]

Viruses
Vittucci AC, Antilici L, Salvatori A, De Rose DU, Scutari R, Di Maio VC, Rotondi Aufiero L, Pisani M, Musolino AM, Dotta A, Perno CF, Villani A.   +11 more
europepmc   +1 more source

Safety of nirsevimab in children aged 0-24 months: Analysis based on EudraVigilance data (2023-2025). [PDF]

Hum Vaccin Immunother
Morciano C, Annunziata A, Cutillo M, Mayer F, Spila Alegiani S.   +4 more
europepmc   +1 more source

Effectiveness of Nirsevimab Reimmunization against Respiratory Syncytial Virus Hospitalization During the Second Season in High-Risk Children. [PDF]

J Pediatric Infect Dis Soc
Monge S, Núñez O, Pastor-Barriuso R, On Behalf Of The Nirsevimab Effectiveness Study Collaborators.   +3 more
europepmc   +1 more source

What is the Optimal RSV Immunization Strategy for Infants Born in the RSV Off-season? [PDF]

J Infect Dis
Moore HC, Foo D, Giannini F, Minney-Smith C, Blyth CC, Richmond PC, Effler P, Sarna M, STAMP RSV Investigators , the.   +9 more
europepmc   +1 more source

Mutational constraints on RSV F and its neutralization by antibodies. [PDF]

Nature
Simonich CAL, McMahon TE, Juviler G, Kampman L, Chu HY, Bloom JD.   +5 more
europepmc   +1 more source